$0.800000
-0.02-2.44%
At Close: -
$0.817000
0.022.12%
After Hours: Jul 5, 7:10 PM EDT
15 minutes delayed
Compass Therapeutics
CMPXNASDAQ
want to know what
the Bulls & Bears Say?
Compass Therapeutics (NASDAQ:CMPX) Stock, Analyst Ratings, Price Targets, Forecasts
Compass Therapeutics Inc has a consensus price target of $9.75 based on the ratings of 22 analysis. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on June 3, 2024, May 16, 2024, and May 14, 2024, respectively. With an average price target of $10 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 1123.99% upside for Compass Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Jefferies
Stifel
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Compass Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/03/2024 | Buy Now | 1123.99% | HC Wainwright & Co. | Joseph Pantginis | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 1123.99% | HC Wainwright & Co. | Joseph Pantginis | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 1123.99% | HC Wainwright & Co. | Joseph Pantginis | → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | 1123.99% | HC Wainwright & Co. | Joseph Pantginis | → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | 879.19% | Wedbush | Robert Driscoll | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 03/21/2024 | Buy Now | 1123.99% | HC Wainwright & Co. | Joseph Pantginis | — | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | 1123.99% | HC Wainwright & Co. | Joseph Pantginis | → $10 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | Buy Now | 1123.99% | HC Wainwright & Co. | Joseph Pantginis | → $10 | Reiterates | → Buy | Get Alert |
| 01/31/2023 | Buy Now | 879.19% | Jefferies | Maury Raycroft | → $8 | Initiates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 1001.59% | Stifel | Stephen Willey | → $9 | Initiates | → Buy | Get Alert |
| 12/16/2022 | Buy Now | 1160.71% | EF Hutton | Michael King | → $10.3 | Initiates | → Buy | Get Alert |
| 11/10/2022 | Buy Now | 879.19% | Raymond James | Dane Leone | $5 → $8 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 1123.99% | HC Wainwright & Co. | Joseph Pantginis | $12 → $10 | Maintains | Buy | Get Alert |
| 05/23/2022 | Buy Now | 1368.79% | HC Wainwright & Co. | Joseph Pantginis | → $12 | Assumes | → Buy | Get Alert |
| 05/05/2022 | Buy Now | 1246.39% | SVB Leerink | Andrew Berens | $9 → $11 | Maintains | Outperform | Get Alert |
| 03/15/2022 | Buy Now | 756.79% | Ladenburg Thalmann | Aydin Huseynov | → $7 | Initiates | → Buy | Get Alert |
| 01/19/2022 | Buy Now | 1123.99% | B. Riley Securities | Justin Walsh | → $10 | Initiates | → Buy | Get Alert |
| 12/22/2021 | Buy Now | 512% | Raymond James | Dane Leone | → $5 | Initiates | → Outperform | Get Alert |
| 12/20/2021 | Buy Now | 1368.79% | SVB Leerink | Andrew Berens | — | Initiates | → Outperform | Get Alert |
| 12/15/2021 | Buy Now | 879.19% | Wedbush | Robert Driscoll | — | Initiates | → Outperform | Get Alert |
| 11/19/2021 | Buy Now | 1735.99% | Roth Capital | Tony Butler | — | Initiates | → Buy | Get Alert |
| 10/20/2021 | Buy Now | 1246.39% | HC Wainwright & Co. | Michael King | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Compass Therapeutics (CMPX) stock?
The latest price target for Compass Therapeutics (NASDAQ:CMPX) was reported by HC Wainwright & Co. on June 3, 2024. The analyst firm set a price target for $10.00 expecting CMPX to rise to within 12 months (a possible 1123.99% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Compass Therapeutics (CMPX)?
The latest analyst rating for Compass Therapeutics (NASDAQ:CMPX) was provided by HC Wainwright & Co., and Compass Therapeutics reiterated their buy rating.
When was the last upgrade for Compass Therapeutics (CMPX)?
There is no last upgrade for Compass Therapeutics
When was the last downgrade for Compass Therapeutics (CMPX)?
There is no last downgrade for Compass Therapeutics.
When is the next analyst rating going to be posted or updated for Compass Therapeutics (CMPX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Compass Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Compass Therapeutics was filed on June 3, 2024 so you should expect the next rating to be made available sometime around June 3, 2025.
Is the Analyst Rating Compass Therapeutics (CMPX) correct?
While ratings are subjective and will change, the latest Compass Therapeutics (CMPX) rating was a reiterated with a price target of $10.00 to $10.00. The current price Compass Therapeutics (CMPX) is trading at is $0.82, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.